Natco Pharma launches generic hepatitis C drug in India
- US stocks flat, investors await Fed decision on policy rates
- Drug price regulator fixes ceiling price of 39 more drug formulations
- Jimmy Kimmel rips Republican health bill for failing ‘Kimmel test’
- Bihar govt orders probe as canal wall awaiting Nitish inauguration collapses
- UK fund sells Bank of Baroda shares worth Rs1,115 crore
New Delhi: Natco Pharma on Monday said it has launched generic sofosbuvir 400 mg/velpatasvir 100 mg tablets, used for treatment of chronic hepatitis C, in India.
The company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name ‘Velpanat’, Natco Pharma said in a BSE filing.
The company’s product is generic version of Gilead Sciences Inc’s Epclusa tablets. Epclusa is used to treat adults with chronic hepatitis C genotype 1 to 6 with or without cirrhosis, Natco Pharma said.
Natco priced its generic tablets at an MRP of Rs 18,500 for a bottle of 28 tablets in India, the company said.
The company “has signed a non-exclusive licensing agreement with Gilead Sciences Inc to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries, it added.
Shares of Natco Pharma were trading 0.77% up at Rs 908.50 on BSE.